These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 26828974

  • 1. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T.
    Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
    [Abstract] [Full Text] [Related]

  • 2. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E.
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [Abstract] [Full Text] [Related]

  • 3. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A.
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [Abstract] [Full Text] [Related]

  • 5. Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.
    Lozano-Ortega G, Walker DR, Johnston K, Mickle A, Harrigan S, Rogula B, Kristy RM, Hairston JC, Schermer CR.
    Drugs Aging; 2020 Nov; 37(11):801-816. PubMed ID: 32960422
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C.
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [Abstract] [Full Text] [Related]

  • 8. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY.
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [Abstract] [Full Text] [Related]

  • 9. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [Abstract] [Full Text] [Related]

  • 10. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 11. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
    Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE.
    Int J Clin Pract; 2013 Jul; 67(7):619-32. PubMed ID: 23692526
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
    Nazir J, Kelleher C, Aballéa S, Maman K, Hakimi Z, Mankowski C, Odeyemi I.
    Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
    [Abstract] [Full Text] [Related]

  • 13. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M, Nukui A, Kamai T.
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J, Hakimi Z, Guelfucci F, Khemiri A, Fatoye F, Blázquez AMM, González MH.
    BMC Urol; 2018 Sep 04; 18(1):76. PubMed ID: 30180826
    [Abstract] [Full Text] [Related]

  • 15. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
    Nitti VW, Chapple CR, Walters C, Blauwet MB, Herschorn S, Milsom I, Auerbach S, Radziszewski P.
    Int J Clin Pract; 2014 Aug 04; 68(8):972-85. PubMed ID: 24703195
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
    Khullar V, Cambronero J, Angulo JC, Wooning M, Blauwet MB, Dorrepaal C, Martin NE.
    BMC Urol; 2013 Sep 18; 13():45. PubMed ID: 24047126
    [Abstract] [Full Text] [Related]

  • 17. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
    Angulo JC, Khullar V, Nitti VW, Siddiqui E.
    Actas Urol Esp; 2013 Sep 18; 37(10):640-51. PubMed ID: 23850394
    [Abstract] [Full Text] [Related]

  • 18. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR.
    Health Qual Life Outcomes; 2018 Apr 19; 16(1):69. PubMed ID: 29673355
    [Abstract] [Full Text] [Related]

  • 19. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ, Cho ST, Kuo HC, Chou EC, Hsu YC, Lee KS, Hadi F, Song Y, Sumarsono B.
    Adv Ther; 2024 Apr 19; 41(4):1652-1671. PubMed ID: 38430402
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
    Schiavi MC, Faiano P, D'Oria O, Zullo MA, Muzii L, Benedetti Panici P.
    J Obstet Gynaecol Res; 2018 Mar 19; 44(3):524-531. PubMed ID: 29271106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.